TY - JOUR
T1 - Performance evaluation of three liquid chromatography mass spectrometry methods for broad spectrum drug screening
AU - Lynch, Kara L.
AU - Breaud, Autumn R.
AU - Vandenberghe, Hilde
AU - Wu, Alan H.B.
AU - Clarke, William
N1 - Funding Information:
This study was supported in part by the HIV Prevention Trials Network (HPTN) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) , National Institute on Drug Abuse (NIDA) , National Institute of Mental Health (NIMH) , and Office of AIDS Research, of the NIH, DHHS ( U01-AI-068613 ).
PY - 2010/10
Y1 - 2010/10
N2 - Background: Liquid chromatography-mass spectrometry (LC-MS) and tandem LC-MS (LC-MS/MS) are increasingly used in toxicology laboratories as a complementary method to gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-ultraviolet detection (LC-UV) for comprehensive drug screening (CDS). This study was designed to characterize the sensitivity and specificity of three LC-MS(/MS) vendor-supplied methods for targeted CDS and identify the current limitations associated with the use of these technologies. Methods: Five methods for broad spectrum CDS, including LC-UV (REMEDi), full scan GC-MS, LC-MS (ZQ™-Mass Detector with MassLynx™-software), LC-QTRAP-MS/MS (3200-QTRAP® with Cliquid®-software) and LC-LIT-MS/MS (LXQ™ Linear Ion Trap with ToxID™-software) were evaluated based on their ability to detect drugs in 48 patient urine samples. Results: The tandem MS methods identified 15% more drugs than the single stage MS or LC-UV methods. Use of two broad spectrum screening methods identified more drugs than any single system alone. False negatives and false positives generated by the LC-MS(/MS) software programs were identified upon manual review of the raw data. Conclusions: The LC-MS/MS methods detected a broader menu of drugs; however, it is essential to establish manual data review criteria for all LC-MS(/MS) drug screening methods. Use of an EI-GC-MS and ESI-LC-MS/MS combination for targeted CDS may be optimal due to the complementary nature of the chromatographic and ionization techniques.
AB - Background: Liquid chromatography-mass spectrometry (LC-MS) and tandem LC-MS (LC-MS/MS) are increasingly used in toxicology laboratories as a complementary method to gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-ultraviolet detection (LC-UV) for comprehensive drug screening (CDS). This study was designed to characterize the sensitivity and specificity of three LC-MS(/MS) vendor-supplied methods for targeted CDS and identify the current limitations associated with the use of these technologies. Methods: Five methods for broad spectrum CDS, including LC-UV (REMEDi), full scan GC-MS, LC-MS (ZQ™-Mass Detector with MassLynx™-software), LC-QTRAP-MS/MS (3200-QTRAP® with Cliquid®-software) and LC-LIT-MS/MS (LXQ™ Linear Ion Trap with ToxID™-software) were evaluated based on their ability to detect drugs in 48 patient urine samples. Results: The tandem MS methods identified 15% more drugs than the single stage MS or LC-UV methods. Use of two broad spectrum screening methods identified more drugs than any single system alone. False negatives and false positives generated by the LC-MS(/MS) software programs were identified upon manual review of the raw data. Conclusions: The LC-MS/MS methods detected a broader menu of drugs; however, it is essential to establish manual data review criteria for all LC-MS(/MS) drug screening methods. Use of an EI-GC-MS and ESI-LC-MS/MS combination for targeted CDS may be optimal due to the complementary nature of the chromatographic and ionization techniques.
KW - Comprehensive drug screening
KW - General unknown screening
KW - Liquid chromatography
KW - Mass spectrometry
UR - http://www.scopus.com/inward/record.url?scp=77955050026&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77955050026&partnerID=8YFLogxK
U2 - 10.1016/j.cca.2010.05.046
DO - 10.1016/j.cca.2010.05.046
M3 - Article
C2 - 20540936
AN - SCOPUS:77955050026
SN - 0009-8981
VL - 411
SP - 1474
EP - 1481
JO - Clinica Chimica Acta
JF - Clinica Chimica Acta
IS - 19-20
ER -